A combined glucagonoma and VIPoma syndrome: First pathologic and clinical report

P. Cavallo-Perin; M. De Paoli; G. Guiso; A. Sapino; M. Papotti; R. Coda; G. Pagano

A combined glucagonoma and VIPoma syndrome: First pathologic and clinical report

P. Cavallo-Perin, M. De Paoli, G. Guiso, A. Sapino, M. Papotti, R. Coda, G. Pagano

Istituto Oncologico Candiolo

Research output: Contribution to journal › Article › peer-review

Abstract

We report a case of pancreatic tumour metastatic to the liver in a patient with insulin-treated diabetes, anaemia, cheilitis, necrolytic migratory erythema, hypokalemia and chronic watery diarrhea, a picture suggesting combined glucagonoma and VIPoma syndromes. Immunocytochemistry of a biopsied hepatic metastatic nodule revealed both glucagon and vasoactive intestinal peptide (VIP) positive cells. Increased plasma glucagon and VIP levels were detected (values of 900 pmol/l and 277 pmol/l respectively). This is the first reported case showing not only immunocytochemical, but also clinical evidence of the combined secretion of these hormones.

Original language	English
Pages (from-to)	2576-2579
Number of pages	4
Journal	Cancer
Volume	62
Issue number	12
Publication status	Published - 1988

ASJC Scopus subject areas

Cancer Research
Oncology

Fingerprint Dive into the research topics of 'A combined glucagonoma and VIPoma syndrome: First pathologic and clinical report'. Together they form a unique fingerprint.

Cite this

@article{c7820f3497334ef08ee42cfac5085c2c,

title = "A combined glucagonoma and VIPoma syndrome: First pathologic and clinical report",

abstract = "We report a case of pancreatic tumour metastatic to the liver in a patient with insulin-treated diabetes, anaemia, cheilitis, necrolytic migratory erythema, hypokalemia and chronic watery diarrhea, a picture suggesting combined glucagonoma and VIPoma syndromes. Immunocytochemistry of a biopsied hepatic metastatic nodule revealed both glucagon and vasoactive intestinal peptide (VIP) positive cells. Increased plasma glucagon and VIP levels were detected (values of 900 pmol/l and 277 pmol/l respectively). This is the first reported case showing not only immunocytochemical, but also clinical evidence of the combined secretion of these hormones.",

author = "P. Cavallo-Perin and {De Paoli}, M. and G. Guiso and A. Sapino and M. Papotti and R. Coda and G. Pagano",

year = "1988",

language = "English",

volume = "62",

pages = "2576--2579",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "12",

}

TY - JOUR

T1 - A combined glucagonoma and VIPoma syndrome

T2 - First pathologic and clinical report

AU - Cavallo-Perin, P.

AU - De Paoli, M.

AU - Guiso, G.

AU - Sapino, A.

AU - Papotti, M.

AU - Coda, R.

AU - Pagano, G.

PY - 1988

Y1 - 1988

N2 - We report a case of pancreatic tumour metastatic to the liver in a patient with insulin-treated diabetes, anaemia, cheilitis, necrolytic migratory erythema, hypokalemia and chronic watery diarrhea, a picture suggesting combined glucagonoma and VIPoma syndromes. Immunocytochemistry of a biopsied hepatic metastatic nodule revealed both glucagon and vasoactive intestinal peptide (VIP) positive cells. Increased plasma glucagon and VIP levels were detected (values of 900 pmol/l and 277 pmol/l respectively). This is the first reported case showing not only immunocytochemical, but also clinical evidence of the combined secretion of these hormones.

AB - We report a case of pancreatic tumour metastatic to the liver in a patient with insulin-treated diabetes, anaemia, cheilitis, necrolytic migratory erythema, hypokalemia and chronic watery diarrhea, a picture suggesting combined glucagonoma and VIPoma syndromes. Immunocytochemistry of a biopsied hepatic metastatic nodule revealed both glucagon and vasoactive intestinal peptide (VIP) positive cells. Increased plasma glucagon and VIP levels were detected (values of 900 pmol/l and 277 pmol/l respectively). This is the first reported case showing not only immunocytochemical, but also clinical evidence of the combined secretion of these hormones.

UR - http://www.scopus.com/inward/record.url?scp=0024209395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024209395&partnerID=8YFLogxK

M3 - Article

C2 - 2847862

AN - SCOPUS:0024209395

VL - 62

SP - 2576

EP - 2579

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -